AU2003267447B8 - Use of valsartan or its metabolite to inhibit platelet aggregation - Google Patents

Use of valsartan or its metabolite to inhibit platelet aggregation Download PDF

Info

Publication number
AU2003267447B8
AU2003267447B8 AU2003267447A AU2003267447A AU2003267447B8 AU 2003267447 B8 AU2003267447 B8 AU 2003267447B8 AU 2003267447 A AU2003267447 A AU 2003267447A AU 2003267447 A AU2003267447 A AU 2003267447A AU 2003267447 B8 AU2003267447 B8 AU 2003267447B8
Authority
AU
Australia
Prior art keywords
valsartan
platelet aggregation
metabolite
pharmaceutically acceptable
valeryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003267447A
Other languages
English (en)
Other versions
AU2003267447A1 (en
AU2003267447B2 (en
Inventor
Alex Malinin
Victor L Serebruany
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29423705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003267447(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003267447A1 publication Critical patent/AU2003267447A1/en
Application granted granted Critical
Publication of AU2003267447B2 publication Critical patent/AU2003267447B2/en
Publication of AU2003267447B8 publication Critical patent/AU2003267447B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003267447A 2002-05-14 2003-05-13 Use of valsartan or its metabolite to inhibit platelet aggregation Ceased AU2003267447B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38037302P 2002-05-14 2002-05-14
US60/380,373 2002-05-14
US39501402P 2002-07-11 2002-07-11
US60/395,014 2002-07-11
PCT/EP2003/004997 WO2003094915A1 (en) 2002-05-14 2003-05-13 Use of valsartan ot its metabolite to inhibit platelet aggregation

Publications (3)

Publication Number Publication Date
AU2003267447A1 AU2003267447A1 (en) 2003-11-11
AU2003267447B2 AU2003267447B2 (en) 2006-11-02
AU2003267447B8 true AU2003267447B8 (en) 2009-08-06

Family

ID=29423705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267447A Ceased AU2003267447B8 (en) 2002-05-14 2003-05-13 Use of valsartan or its metabolite to inhibit platelet aggregation

Country Status (22)

Country Link
US (2) US20050197372A1 (https=)
EP (1) EP1505965B1 (https=)
JP (1) JP4467427B2 (https=)
KR (1) KR101005367B1 (https=)
CN (1) CN100408035C (https=)
AT (1) ATE334677T1 (https=)
AU (1) AU2003267447B8 (https=)
BR (1) BR0310018A (https=)
CA (1) CA2482541A1 (https=)
CY (1) CY1105638T1 (https=)
DE (1) DE60307265T2 (https=)
DK (1) DK1505965T3 (https=)
ES (1) ES2268403T3 (https=)
IL (2) IL164774A0 (https=)
MX (1) MXPA04011282A (https=)
NO (1) NO20045245L (https=)
NZ (1) NZ536295A (https=)
PL (1) PL371728A1 (https=)
PT (1) PT1505965E (https=)
RU (1) RU2334512C2 (https=)
TW (1) TWI299663B (https=)
WO (1) WO2003094915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
US10478404B2 (en) 2014-01-24 2019-11-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, methods and devices for altering cell reactivity
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法
CN111643557B (zh) * 2020-05-26 2022-02-22 四川省骨科医院 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312198T1 (de) * 1993-04-05 2005-12-15 Univ Utah Res Found Diagnose und behandlung von supravalvular aortic stenosis
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate

Also Published As

Publication number Publication date
AU2003267447A1 (en) 2003-11-11
KR20050000532A (ko) 2005-01-05
JP4467427B2 (ja) 2010-05-26
ATE334677T1 (de) 2006-08-15
DE60307265T2 (de) 2007-07-19
CN1652774A (zh) 2005-08-10
HK1074395A1 (en) 2005-11-11
PL371728A1 (en) 2005-06-27
CY1105638T1 (el) 2010-12-22
TW200410686A (en) 2004-07-01
NZ536295A (en) 2006-12-22
US20100048654A1 (en) 2010-02-25
JP2005529913A (ja) 2005-10-06
PT1505965E (pt) 2006-11-30
MXPA04011282A (es) 2005-01-25
AU2003267447B2 (en) 2006-11-02
WO2003094915A1 (en) 2003-11-20
BR0310018A (pt) 2005-02-15
CA2482541A1 (en) 2003-11-20
KR101005367B1 (ko) 2010-12-30
IL164774A0 (en) 2005-12-18
DK1505965T3 (da) 2006-11-13
EP1505965A1 (en) 2005-02-16
RU2334512C2 (ru) 2008-09-27
RU2004136583A (ru) 2005-09-10
IL164774A (en) 2010-04-29
US20050197372A1 (en) 2005-09-08
ES2268403T3 (es) 2007-03-16
DE60307265D1 (de) 2006-09-14
CN100408035C (zh) 2008-08-06
TWI299663B (en) 2008-08-11
EP1505965B1 (en) 2006-08-02
NO20045245L (no) 2004-11-30

Similar Documents

Publication Publication Date Title
US20100048654A1 (en) Use of valsartan or its metabolite to in hibit platelet aggregation
JP6980767B2 (ja) ニコチニルアルコールエーテル誘導体、調製及び医薬組成物及び使用
JP2789134B2 (ja) 糖尿病の合併症を制御する置換ピリミジン類
EP3749326A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
US5053420A (en) Thiazolidine derivatives for the treatment of hypertension
WO2006074265A2 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2013147161A1 (ja) ニペコチン酸誘導体及びその医薬用途
WO2001058443A1 (fr) INHIBITEURS DE TNF-$g(a)
JP4593271B2 (ja) 抗炎症性組成物および使用の方法
HK1074395B (en) Use of the metabolite of valsartan to inhibit platelet aggregation
WO2013161980A1 (ja) シクロヘキサンジアミド誘導体及びその医薬用途
JPH0678230B2 (ja) 好中球によるエラスターゼの遊離の阻害剤としてのテニダップ
JP2002326957A (ja) 慢性閉塞性肺疾患の治療方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ USE OF VALSARTAN OR ITS METABOLITE TO INHIBIT PLATELET AGGREGATION

FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 20, NO 42, PAGE(S) 4177 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME NOVARTIS AG, APPLICATION NO. 2003267447, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24 NOVEMBER 2003

Free format text: IN VOL 18, NO 2, PAGE(S) 561 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME NOVARTIS AG, APPLICATION NO. 2003267447, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24 NOVEMBER 2003

MK14 Patent ceased section 143(a) (annual fees not paid) or expired